Share LinkedIn Email Copy Link While some biopharma companies beat expectations, others fell short for various reasons, with some deciding to return or axe assets.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024